Yunshi Cai

Yunshi Cai

Auto-generated profile, based on publicly available information

Yunshi Cai

Liver Transplant Center, Transplant Center, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital Sichuan University and Collaborative Innovation Center of Biotherapy Chengdu China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Cancer Medicine
Verified
Journal Article
Open access
JZJiang Zhu
Jiang Zhu
CLChang Liu
Chang Liu
HLHui Li
Hui Li
HRHaoyu Ren
Haoyu Ren
YCYunshi Cai
Yunshi Cai
HWHong Wu
Hong Wu
Purpose: To comprehensively investigate the implications of lymph node dissection (LND) and the prognostic impact of the number of lymph node (LN) metastases on survival in intrahepatic cholangiocarcinoma (ICC) using a large‐scale study.Methods: Patients who underwent surgical resection for ICC between 2004 and 2018 were identified from the Surveillance, Epidemiology, and End Results (SEER) registries. The Kaplan–Meier and log‐rank tests were used to compare cancer‐specific survival (CSS) and overall survival (OS) between different groups. Propensity score matching (PSM) and subgroup analyses were performed to balance potential confounding factors. A multivariate Cox proportional hazards regression model was used to identify prognostic factors of survival outcomes. Restricted cubic splines fitted in the Cox proportional hazard regression models were also conducted to examine associations between continuous variables and outcomes.Results: In all, 1028 patients were enrolled. There were 652 (63.4%) patients undergoing LND, with lymph node metastasis (LNM) confirmed in 212 (32.5%) cases. Patients receiving LND did not show better survival outcomes than those receiving non‐LND (NLND). We divided the LND group into two subgroups: patients with LNM (+) and those without LNM (−). Among these three groups, patients with LNM experienced the worst CSS and OS, while NLND patients had similar survival times to LNM (−) patients. Restricted cubic spline analysis indicated that an increased number of LNM was associated with a decreased chance of survival (p < 0.001). Patients who received LND were further categorized as having no nodal metastasis (N0), 1–2 LNM (N1), or ≥3 LNM (N2) according to the number of LNM. The Kaplan–Meier curves showed that the mortality risk of patients with N0, N1, and N2 disease (median CSS, N0 50.0 vs. N1 22.0 vs. N2 14.0 months; median OS, N0 46.0 vs. N1 21.0 vs. N2 14.0 months, all p < 0.01) increased significantly, except for patients who had <6 LNs harvested. On multivariable survival analysis, a higher nodal stage (N1 vs. N0: CSS, hazard ratio [HR] 2.135, 95% CI 1.636–2.788, p < 0.001; OS, HR 2.100, 95% CI 1.624–2.717, p < 0.001; N2 vs. N0: CSS, HR 4.027, 95% CI 2.791–5.811, p < 0.001; OS, HR 3.678, 95% CI 2.561–5.282, p < 0.001) was an independent prognostic risk factor for survival.Conclusions: Despite the lack of a clear survival benefit of LND in patients with ICC, a significant positive association between the number of LNM and poor outcomes was observed. We still suggest adequate LND by examining at least six LNs to ensure precise staging. On this basis, the recently proposed nodal classification of N0, N1, and N2 stages may also allow better prognostic stratification of ICC patients.

18 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
YCYunshi Cai
Yunshi Cai
KXKunlin Xie
Kunlin Xie
MAMohammad Natheir Adeeb Alhmoud
Mohammad Natheir Adeeb Alhmoud
TLTian Lan
Tian Lan
HWHaifeng Wan
Haifeng Wan
HWHong Wu
Hong Wu
Background: Prothrombin induced by vitamin K absence‐II (PIVKA‐II) and Alpha‐fetoprotein (AFP) have been widely used as diagnostic markers in hepatocellular carcinoma (HCC), but the prognostic values of the two serum markers and their clinical usefulness in patient selection for different surgical approaches remain largely unclear.Methods: HCC patients received surgical treatment between 2015 and 2019 were included. Patients were divided into four statuses according to the serum PIVKA‐II and AFP secretion status: PIVKA‐II (−) AFP (−) (status 1); PIVKA‐II (+) AFP (−) (status 2); PIVKA‐II (−) AFP (+) (status 3); PIVKA‐II (+) AFP (+) (status 4). Kaplan–Meier analyses were conducted to compare the survivals of the four groups and the HCC patients received different surgical interventions; time‐dependent AUC curves were introduced to evaluate the prognostic value of the PIV‐AFP status; Cox regression model was used to identify prognostic indexes for overall survival (OS) and recurrence‐free survival (RFS).Results: A total of 518 patients were included. Patients with PIVKA‐II (+) and APF (+) presented significantly decreased OS and RFS comparing to the other statuses. The areas under ROC curves of PIV‐AFP status in predicting OS and RFS were superior to the PIVKA‐II or the AFP alone. The HCC patients in early stages with PIVKA‐II (+) and APF (+) had worse RFS when received laparoscopic hepatectomy than those who received open hepatectomy, whereas there was no difference in other secretion statuses. The PIVKA‐II (+) and AFP (+) secretion status was an independent risk factor for OS, RFS.Conclusions: The PIV‐AFP secretion status is of favorable clinical utility in predicting the OS and RFS of the HCC patients; extra caution is needed when applicated the laparoscopic approach in the HCC patients with PIVKA‐II (+) and AFP (+).

1 February 2022 in HepatoBiliary Surgery and Nutrition
Verified
Journal Article
Open access
PDF file
YCYun-Shi Cai
Yun-Shi Cai
HWHong Wu
Hong Wu
Is FOLFOX-HAIC superior to transarterial chemoembolization in treating large hepatocellular carcinoma? Yun-Shi Cai, Hong Wu